What question did this study set out to answer?

To assess the efficacy and safety of HSK39297, a CFB inhibitor, in patients with primary immunoglobulin A nephropathy.

March 28, 2026Open Access

Wcn26-5558 Efficacy and Safety of Hsk39297, a Once-Daily Oral CFB Inhibitor, in Patients With Primary Immunoglobulin a Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial

Key Points

To assess the efficacy and safety of HSK39297, a CFB inhibitor, in patients with primary immunoglobulin A nephropathy.
Conducted a randomized, double-blind, placebo-controlled trial
Compared the effects of HSK39297 versus a placebo
Monitored metabolic changes and kidney function in participants
Significant metabolic alterations were observed with long-term low-dose phosphorus loading
Reduced lifespan noted without hyperphosphatemia
Sex-specific differences in outcomes were identified, likely influenced by sex hormones

Abstract

Conclusion:Long-term, low-dose phosphorus loading induces significant metabolic alterations and reduced lifespan without hyperphosphatemia, with sex-specific manner likely influenced by sex hormones.Our experimental models provide new insights into the sexspecific outcomes observed in chronic kidney disease patients, who are particularly susceptible to phosphorus dysregulation.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Bookmark

View Full Paper

Cite This Study

Lv et al. (Wed,) studied this question.

synapsesocial.com/papers/69c770888bbfbc51511e08ec https://doi.org/https://doi.org/10.1016/j.ekir.2026.104480

Bookmark

View Full Paper